Cancer Moonshot

Science in Space to Cure Disease on Earth--the International Space Station National Lab and NASA Announce New Funding Opportunity

Retrieved on: 
Mercredi, août 9, 2023
Learning, White House, Cell biology, Partnership, Therapy, Life, SPACE, Biotechnology, Cancer, Quality of life, ISS National Lab, International Space Station, Research, Scientific research on the International Space Station, College of Engineering (KNUST), United States national laboratories, EDT, Biology, White, Regenerative medicine, NLRA, Chemistry, NASA, Patient, Tissue engineering, Artemis, China Institute for Innovation and Development Strategy, Cancer Moonshot, Diagnosis, Government, American Cancer Society, Health, Step, ISS, Disease, Pharmaceutical industry, Science

KENNEDY SPACE CENTER, Fla., Aug. 9, 2023 /PRNewswire/ -- The International Space Station (ISS) National Laboratory is collaborating with NASA on a solicitation to advance research on cancer and other diseases.

Key Points: 
  • KENNEDY SPACE CENTER, Fla., Aug. 9, 2023 /PRNewswire/ -- The International Space Station (ISS) National Laboratory is collaborating with NASA on a solicitation to advance research on cancer and other diseases.
  • Cancer and other disease-related research on the space station is of critical importance not only to the ISS National Lab and NASA but also to the Biden-Harris administration.
  • Partnering with the ISS National Lab on this research is another exciting step toward supporting astronaut health during future Artemis missions."
  • Those interested in learning more about this research announcement can attend a webinar hosted by the ISS National Lab on August 24, 2023, at 1 p.m. EDT.

SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2023

Retrieved on: 
Mardi, août 8, 2023
Operating cost, White House, Tulane University School of Medicine, Eastern Time Zone, Education, Central European Summer Time, Marketing, NGS, COVID-19, Microsoft, H. Lee Moffitt Cancer Center & Research Institute, Research, COVID, Biomarker, History, Forecasting, White, Sophia, Constant, Sophia Genetics, Lila Tretikov, Blood, Memorial Sloan Kettering Cancer Center, GENETICS, Corporation, Cancer Moonshot, Artificial intelligence, Growth, Annual general meeting, Video game, Pharmaceutical industry, Wikimedia Foundation

Gross margin was 67% for the second quarter of 2023 compared with 65% for the second quarter of 2022.

Key Points: 
  • Gross margin was 67% for the second quarter of 2023 compared with 65% for the second quarter of 2022.
  • Adjusted gross margin was 70% for the second quarter of 2023 compared to 67% for the second quarter of 2022.
  • R&D expenses for the second quarter of 2023 were $8.9 million compared to $9.0 million for the second quarter of 2022.
  • Operating loss for the second quarter of 2023 was $20.0 million compared to $24.1 million in the second quarter of 2022.

Reigniting the Cancer Moonshot: Massive Bio Joins CancerX as Founding Member to Accelerate Innovation and AI Implementation in Cancer Care

Retrieved on: 
Dimanche, juin 4, 2023
Technology, Research, Clinical Trials, Biotechnology, Health, Other Science, Science, Artificial Intelligence, Oncology, Cloud, White House, Partnership, Drug development, SBIR, Clinical trial, Cancer, Intelligence, Toxicity, Multimedia, Movement, ASCO, Cancer Moonshot, Incidence, National Cancer Institute, M&A, H. Lee Moffitt Cancer Center & Research Institute, Patient, Entrepreneurship, Digital, AI, Dime, Pharmaceutical industry, Vaccine

This appointment situates Massive Bio at the forefront of a national public-private partnership aiming to revolutionize the fight against cancer.

Key Points: 
  • This appointment situates Massive Bio at the forefront of a national public-private partnership aiming to revolutionize the fight against cancer.
  • View the full release here: https://www.businesswire.com/news/home/20230604005029/en/
    FINAL CancerX Founding Members Logo Cloud (Graphic: Business Wire)
    As cancer continues to pose a significant global challenge, Massive Bio stands committed to mitigating this scourge.
  • Being chosen as a founding member of CancerX confirms our dedication to advancing precision oncology and democratizing access to groundbreaking cancer treatments.
  • CancerX is primarily focused on advancing digital innovation to improve equity and reduce financial toxicity in cancer care and research.

Volpara Health Joins CancerX

Retrieved on: 
Vendredi, juin 2, 2023
White House, Communication, Partnership, Life, Yale Physician Associate Program, Policy, American Society of Clinical Oncology, Cancer, ASX, VHT, Volpara, Cancer Moonshot, Incidence, Multi, Health, Society, Dime, Pharmaceutical industry

LYNNWOOD, Wash., June 2, 2023 /PRNewswire/ -- Volpara Health Technologies Ltd. (ASX: VHT) proudly announces its founding membership in CancerX, a public-private partnership aimed at revolutionizing cancer innovation in the United States. As a global leader in cancer detection software, Volpara joins other leaders in advancing patient care, communication, and policy in the fight against this devastating disease.

Key Points: 
  • LYNNWOOD, Wash., June 2, 2023 /PRNewswire/ -- Volpara Health Technologies Ltd. (ASX: VHT) proudly announces its founding membership in CancerX , a public-private partnership aimed at revolutionizing cancer innovation in the United States.
  • As a global leader in cancer detection software, Volpara joins other leaders in advancing patient care, communication, and policy in the fight against this devastating disease.
  • Andrea Wolf, Public Policy Advisor, Volpara Health, states, "Cancer Moonshot success requires deep collaboration, novel approaches, and focused direction.
  • "Multi-stakeholder collaboration is critical to harness the potential of digital innovation in the fight against cancer, and we're honored to partner with Volpara Health to achieve the ambitious goals of CancerX," said Smit Patel, Associate Program Director at DiMe.

SOPHiA GENETICS Joins CancerX to Help Accelerate Cancer Research

Retrieved on: 
Vendredi, juin 2, 2023
White House, Office of the National Coordinator for Health Information Technology, Business development, Partnership, Office of the Assistant Secretary for Health, Life, Sophia Genetics, Yale Physician Associate Program, Cancer, Intelligence, Research, Assistant, White, ASCO, Cancer Moonshot, Sophia, Incidence, ONC, Data analysis, H. Lee Moffitt Cancer Center & Research Institute, Machine learning, GENETICS, MSK, Memorial Sloan Kettering Cancer Center, Multi, Digital, Dime, Vaccine, Pharmaceutical industry

BOSTON and LAUSANNE, Switzerland, June 2, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced today at ASCO that it has joined as a founding member of CancerX, a new public-private partnership formed to rapidly accelerate the pace of cancer innovation in the United States. As a founding member, SOPHiA GENETICS will help drive the success of CancerX, collaborating to set priorities and practices that will harness the power of innovation to further cancer care and research. SOPHiA GENETICS offers its SOPHiA DDM™ Platform, powered by artificial intelligence and machine learning, to help advance the inaugural project, which looks to improve equity and reduce cost in cancer treatments. 

Key Points: 
  • As a founding member, SOPHiA GENETICS will help drive the success of CancerX, collaborating to set priorities and practices that will harness the power of innovation to further cancer care and research.
  • "As a leader in data-driven medicine, SOPHiA GENETICS is eager to join forces with CancerX and its partners that will lend their expertise towards expediting cancer research and innovation in the U.S.," said Kevin Puylaert, Vice President, Business Development & Marketing for SOPHiA GENETICS.
  • We look forward to leveraging the collective intelligence that our platform creates to help progress cancer research as we embark on our work with CancerX."
  • The SOPHiA DDM™ Platform will not only help bring CancerX partner data together but will accelerate research work to help facilitate breakthroughs.

Slope, Leader in Modernizing Clinical Trial Execution, Joins CancerX as Founding Member

Retrieved on: 
Vendredi, juin 2, 2023
White House, Office of the National Coordinator for Health Information Technology, Partnership, Office of the Assistant Secretary for Health, Life, Yale Physician Associate Program, Clinical trial, Cancer, White House Conference on Aging, H. Lee Moffitt Cancer Center & Research Institute, Research, Assistant, Cancer Moonshot, Incidence, Slope, ONC, Patient, Digital, Death, News, Dime, Bankruptcy, Pharmaceutical industry, Vaccine

RICHMOND, Va., June 2, 2023 /PRNewswire/ -- Slope, the industry-leading provider of a clinical trial execution platform focusing on clinical inventory and sample management, announced today its role as a founding member of CancerX. This public-private partnership, which is a part of The White House's reignited national Cancer Moonshot, aims to revolutionize cancer research and treatment through the power of digital innovation. CancerX is co-hosted by the Moffitt Cancer Center and the Digital Medicine Society (DiMe), in collaboration with the Office for the National Coordinator for Health Information Technology (ONC) and Office of the Assistant Secretary for Health (OASH).

Key Points: 
  • RICHMOND, Va., June 2, 2023 /PRNewswire/ -- Slope , the industry-leading provider of a clinical trial execution platform focusing on clinical inventory and sample management, announced today its role as a founding member of CancerX .
  • Slope will leverage its expertise in complex oncology clinical trials and tech innovation to accelerate treatments.
  • As a founding member of CancerX, Slope will leverage its expertise in complex oncology clinical trials and technological innovation to accelerate treatments and contribute to the ambitious goal of reducing cancer deaths by 50% over the next 25 years.
  • "We are honored to support CancerX's mission to bring innovation to the fight against cancer," said Hope Meely, Chief Clinical Officer at Slope.

Thyme Care Joins CancerX Innovation Accelerator as Founding Member to Ignite Cancer Moonshot

Retrieved on: 
Vendredi, juin 2, 2023
White House, Office of the National Coordinator for Health Information Technology, Partnership, Office of the Assistant Secretary for Health, Life, Digital, Face, West Midlands CARE Team, Cancer, Quality of life, H. Lee Moffitt Cancer Center & Research Institute, White House Medical Unit, Assistant, Organization, Incidence, ONC, Patient, Risk, Nursing, Diagnosis, Multi, Longevity, Transport, Oncology, Death, Dime, Cancer Moonshot

As a founding member, Thyme Care will help set the strategic direction of the initiative and collaborate on ways to achieve the goals of Cancer Moonshot.

Key Points: 
  • As a founding member, Thyme Care will help set the strategic direction of the initiative and collaborate on ways to achieve the goals of Cancer Moonshot.
  • Cancer Moonshot aims to slash the cancer death rate in half over the next 25 years .
  • It's one of the many reasons why we established Thyme Care," said Bobby Green, co-founder, chief medical officer, and president of Thyme Care.
  • Built by a team of oncology industry veterans , Thyme Care guides patients through their cancer journey by providing comprehensive cancer care navigation and support.

On 'World No Tobacco Day,' Nicokick Supports Smokers' Efforts To Quit With Alternative Products

Retrieved on: 
Mercredi, mai 31, 2023
Cancer Moonshot, World No Tobacco Day, World Health Organization, Smoker, Death, WHO, Carcinogen, Nicotine, Smoking, Tobacco, Public

Less harmful products like pouches , lozenges, and gum help smokers get the nicotine they need with a fraction of the chemicals and carcinogens that come from smoking traditional cigarettes.

Key Points: 
  • Less harmful products like pouches , lozenges, and gum help smokers get the nicotine they need with a fraction of the chemicals and carcinogens that come from smoking traditional cigarettes.
  • "Ensuring consumers have quick access to alternative products via online sales, as well as a variety of flavored products that are preferred by adults, can make the difference for those struggling to quit cigarettes.
  • We cannot expect smokers to quit cold-turkey, which is why Nicokick's alternative products provide a gradual pathway to a harm-reduced lifestyle."
  • Nicokick continues to engage with the Biden administration's Cancer Moonshot initiative and remains confident that embracing less harmful alternative nicotine products save lives.

KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT

Retrieved on: 
Jeudi, mai 25, 2023
White House, Disease, Radiation, Society, Drug development, GBM, Neuro-Oncology (journal), ONC201, Survival, American Association for Cancer Research, Research, Brain, Melanoma, Global Coalition Against Pneumonia, White, II, KZIA, DIPG, Patient, Cancer, Cancer Moonshot, Diagnosis, Diffuse intrinsic pontine glioma, PNOC, Oncology, FDA, Melanoma Research, Caregiver, Medical imaging, Glioblastoma, Kazia Pelka

SYDNEY, May 25, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, has been invited to the White House to participate in the Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) & Diffuse Intrinsic Pontine Glioma (DIPG), to be held on Thursday, 25 May 2023. 

Key Points: 
  • Kazia's CEO, Dr. John Friend, was invited and will be participating in this forum.
  • Friend to participate in the forum reflects the importance of Kazia's work in developing treatments for GBM and DIPG and reconfirms Kazia's position as a global leader in this field.
  • "We are honored to participate in the Cancer Moonshot forum on adult and pediatric brain cancer alongside global Neuro-Oncology thought leaders, researchers, US government officials and patient advocates," stated Dr.
  • GBM is the most aggressive and most common primary brain cancer with a five-year survival rate of approximately 10%.

RevitaLash® Cosmetics and City of Hope Continue Partnership in Support of the Federal Government's Cancer Moonshot

Retrieved on: 
Mercredi, mai 17, 2023
White House, Partnership, City of Hope National Medical Center, City of Hope, Education, Breast cancer, Pathology, Cancer, Woman, Research, Cancer Moonshot, National Cancer Institute, Patient, Nursing, Cosmetics, Diagnosis, Entrepreneurship, Mortality, MPH, Courage, Birth control, City, MD

VENTURA, Calif., May 17, 2023 /PRNewswire/ -- Athena Cosmetics, Inc., parent company to RevitaLash® Cosmetics, has announced a significant investment in City of Hope's Ethiopia Breast Cancer Initiative to improve breast cancer detection, diagnosis, and treatment in the region as part of the Cancer Moonshot, a National Cancer Institute effort reignited by President Biden in 2022 which aims to reduce the death rate from cancer by at least 50% over the next 25 years, and improve the experience of people and families living with and surviving cancer globally, according to a recent White House press release.

Key Points: 
  • The overarching goal of the Ethiopia Breast Cancer Initiative is to increase education and training, thus improving detection, diagnosis, and treatment in an underserved region of the world.
  • Through these initiatives, RevitaLash® Cosmetics and City of Hope will improve breast cancer diagnosis and treatment for over 23 million people served by the hospital in Hawassa, Ethiopia and beyond.
  • "We are committed to our partnership with City of Hope on the Ethiopia Breast Cancer Initiative to improve breast cancer care and treatment in sub-Saharan Africa," said Dr. Michael Brinkenhoff, founder and CEO of RevitaLash® Cosmetics.
  • We look forward to continuing our partnership with RevitaLash Cosmetics and working together to help curb the impact of breast cancer worldwide."